News

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...
Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...
Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of ...